Pharmaceuticals, Biotechnology and Life Sciences
Orexo AB’s nasal spray formulations for opioid overdose reversal has been compared to Narcan in a study, in which it showed similar or better results, the company said in a press release on Monday.
Orexo AB said on Wednesday that Zubsolv tablet’s position has changed from excluded from reimbursement to reimbursed as a preferred product. Zubsolv is buprenorphine and naloxone sublingual tablet (CIII) managed care formulary position with CVS Caremark for patients suffering from opioid dependence.
Another patent infringement against Teva has been filed in recent couple of months. Orexo AB has filed a patent infringement action in United States District Court for the District of Delaware against Actavis Elizabeth LLC, Actavis Pharma, Inc., and their parent company Teva.